The role of galectins in mediating the adhesion of circulating cells to vascular endothelium
Open Access
- 22 May 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1395714
Abstract
Vascular cell adhesion is a complex orchestration of events that commonly feature lectin–ligand interactions between circulating cells, such as immune, stem, and tumor cells, and endothelial cells (ECs) lining post-capillary venules. Characteristically, circulating cell adherence to the vasculature endothelium is initiated through interactions between surface sialo-fucosylated glycoprotein ligands and lectins, specifically platelet (P)- or endothelial (E)-selectin on ECs or between leukocyte (L)-selectin on circulating leukocytes and L-selectin ligands on ECs, culminating in circulating cell extravasation. This lectin–ligand interplay enables the migration of immune cells into specific tissue sites to help maintain effective immunosurveillance and inflammation control, the homing of stem cells to bone marrow or tissues in need of repair, and, unfortunately, in some cases, the dissemination of circulating tumor cells (CTCs) to distant metastatic sites. Interestingly, there is a growing body of evidence showing that the family of β-galactoside-binding lectins, known as galectins, can also play pivotal roles in the adhesion of circulating cells to the vascular endothelium. In this review, we present contemporary knowledge on the significant roles of host- and/or tumor-derived galectin (Gal)-3, -8, and -9 in facilitating the adhesion of circulating cells to the vascular endothelium either directly by acting as bridging molecules or indirectly by triggering signaling pathways to express adhesion molecules on ECs. We also explore strategies for interfering with galectin-mediated adhesion to attenuate inflammation or hinder the metastatic seeding of CTCs, which are often rich in galectins and/or their glycan ligands.Keywords
This publication has 181 references indexed in Scilit:
- Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participantsCancer Chemotherapy and Pharmacology, 2023
- αvβ1 integrin is enriched in extracellular vesicles of metastatic breast cancer cells: A mechanism mediated by galectin‐3Journal of Extracellular Vesicles, 2022
- Stem cell homing: From physiology to therapeuticsStem Cells, 2020
- Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinomaCancer Immunology, Immunotherapy, 2020
- Monosaccharide Derivatives with Low‐Nanomolar Lectin Affinity and High Selectivity Based on Combined Fluorine–Amide, Phenyl–Arginine, Sulfur–π, and Halogen Bond InteractionsChemMedChem, 2018
- Therapeutic potential of Galectin‐9 in human diseaseMedicinal Research Reviews, 2011
- Synthesis of sialyl Lewisa (sLea, CA19-9) and construction of an immunogenic sLea vaccineCancer Immunology, Immunotherapy, 2009
- Galectin-9 expression links to malignant potential of cervical squamous cell carcinomaJournal of Cancer Research and Clinical Oncology, 2008
- Possible role of galectin‐9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significanceInternational Journal of Cancer, 2002
- Galectin‐3 is expressed in the notochord, developing bones, and skin of the postimplantation mouse embryoDevelopmental Dynamics, 1995